Next Article in Journal
Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination
Previous Article in Journal
LincRNAs and snoRNAs in Breast Cancer Cell Metastasis: The Unknown Players
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 18
10.3390/cancers14184529
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Cancers 2019, 11(5), 718.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Pandey et al. ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. Cancers 2019, 11, 718

by
Gaurav Pandey
1,†,
Nicholas Borcherding
1,2,3,†,
Ryan Kolb
4,
Paige Kluz
1,
Wei Li
4,
Sonia Sugg
5,
Jun Zhang
6,
Dazhi A. Lai
7 and
Weizhou Zhang
4,*
1
Department of Pathology, College of Medicine, University of Iowa, Iowa City, IA 52242, USA
2
Cancer Biology Graduate Program, College of Medicine, University of Iowa, Iowa City, IA 52242, USA
3
Medical Scientist Training Program, College of Medicine, University of Iowa, Iowa City, IA 52242, USA
4
Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA
5
Department of Surgery, College of Medicine, University of Iowa, Iowa City, IA 52242, USA
6
Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, College of Medicine, University of Iowa, Iowa City, IA 52242, USA
7
Speed Biosystems, Gaithersburg, MD 20878, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2022, 14(18), 4529; https://doi.org/10.3390/cancers14184529
Submission received: 29 July 2022 / Accepted: 4 September 2022 / Published: 19 September 2022
Versions Notes

Error in Figure

In the original publication [1], there was a mistake in Figure 5g,h as published. The authors made an unintentionally wrong cropping for Figure 5g,h for AKT blots. The corrected Figure 5, appears below. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Cancers 14 04529 i001

Reference

  1. Pandey, G.; Borcherding, N.; Kolb, R.; Kluz, P.; Li, W.; Sugg, S.; Zhang, J.; Lai, D.A.; Zhang, W. ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. Cancers 2019, 11, 718. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Pandey, G.; Borcherding, N.; Kolb, R.; Kluz, P.; Li, W.; Sugg, S.; Zhang, J.; Lai, D.A.; Zhang, W. Correction: Pandey et al. ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. Cancers 2019, 11, 718. Cancers 2022, 14, 4529. https://doi.org/10.3390/cancers14184529

AMA Style

Pandey G, Borcherding N, Kolb R, Kluz P, Li W, Sugg S, Zhang J, Lai DA, Zhang W. Correction: Pandey et al. ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. Cancers 2019, 11, 718. Cancers. 2022; 14(18):4529. https://doi.org/10.3390/cancers14184529

Chicago/Turabian Style

Pandey, Gaurav, Nicholas Borcherding, Ryan Kolb, Paige Kluz, Wei Li, Sonia Sugg, Jun Zhang, Dazhi A. Lai, and Weizhou Zhang. 2022. "Correction: Pandey et al. ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. Cancers 2019, 11, 718" Cancers 14, no. 18: 4529. https://doi.org/10.3390/cancers14184529

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop